NEW YORK – A new study suggests that proteogenomic analyses may be able to match HPV-negative head and neck squamous cell carcinoma subtypes to potential treatment approaches.
Head and neck squamous cell carcinoma (HNSCC) affects about 53,000 people a year in the US, and though some targeted therapies like EGFR monoclonal antibody and PD-1 inhibitor treatments have been approved to treat HNSCC, response rates have been modest.